July 2026

ENDOCRINOLOGY

NORTHWESTERN MEDICINE EXPERTS SHARE CLINICAL TAKEAWAYS FROM ADA 2026

From advances in diabetes technology to evidence-based approaches for managing diabetes during pregnancy, several of our physicians contributed expertise across several key topics at the 2026 American Diabetes Association (ADA) Scientific Sessions.
Among the Northwestern Medicine faculty featured were Grazia Aleppo, MD, a leading expert in diabetes technology, and Emily D. Szmuilowicz, MD, an expert in diabetes management during pregnancy.

Helping Shape National Standards of Care
Our faculty played a prominent role in one of the conference's most anticipated educational programs: The ADA's Standards of Care in Diabetes: 2026 Updates.
During the symposium, Dr. Szmuilowicz presented updates to the chapter “Management of Diabetes in Pregnancy,” highlighting recommendations related to preconception discontinuation of GLP-1 receptor agonists and dual GIP/GLP-1 therapies, as well as the importance of achieving glycemic goals before pregnancy. She also reviewed emerging evidence and ongoing controversies related to the management of mild hyperglycemia detected during early pregnancy.

Spotlight on Diabetes Technology
Dr. Aleppo chaired three featured sessions showcasing some of the meeting's most significant advances in diabetes technology.

In “What's New with Insulin Delivery Systems?,” researchers presented new data on automated insulin delivery (AID) systems, including the Twiist system for people with Type 2 diabetes and a next-generation Omnipod algorithm for people with Type 1 and Type 2 diabetes. The session also featured an ADA President's Select Abstract Presentation Award-winning study demonstrating that AID systems can safely improve glucose management while reducing hypoglycemia risk among hospitalized patients with advanced kidney disease.

Dr. Aleppo also chaired “What's New in Continuous Glucose Monitoring (CGM) Systems?,” which featured results from the CONNECT trial, conducted entirely in primary care settings among people with Type 2 diabetes not using insulin. The findings provided compelling evidence supporting CGM use in Type 2 diabetes and demonstrated its value beyond specialty endocrinology practices and into primary care settings.

A third session, “Diabetes Technology Use Across Life Situations,” explored how diabetes technologies are improving care across the lifespan, as well as for hospitalized patients and people with disabilities.
​
Key Themes From ADA 2026
  • The continued expansion of diabetes technology across Type 1 and Type 2 diabetes
  • Growing adoption of technology in primary care and inpatient settings
  • Promising results from next-generation obesity therapies

Refer a Patient

Northwestern Medicine welcomes the opportunity to collaborate with you in caring for your patients. ​

You May Also Like